Victory Pharma announces launch of additional Naprelan® prescription products

SAN DIEGO (January 8, 2009) –Victory Pharma, Inc., a privately held specialty pharmaceutical company, today announced that it is launching two additional dosage strengths of NAPRELAN® (naproxen sodium) Controlled-Release Tablets. NAPRELAN is a once-daily, controlled-release formulation of naproxen sodium, a non-steroidal anti-inflammatory drug (NSAID) indicated for the treatment of a number of conditions, including osteoarthritis, rheumatoid arthritis and management of mild to moderate pain. VICTORY’S promotional efforts will be directed primarily at pain management specialists, rheumatologists, orthopedic surgeons and selected primary care physicians.

Since January 2007, Victory has promoted the 375 milligram dose of NAPRELAN. Victory plans to commence promotion on 500 milligram and 750 milligram NAPRELAN dose strengths by January 15, 2009. “By promoting these additional strengths of NAPRELAN, we will further leverage our commercial organization and provide the dosing flexibility sought by physicians treating pain and inflammation with NSAIDs,” said Matt Heck, President and Chief Executive Officer of Victory Pharma, Inc. “An important factor in our decision to acquire the U.S. marketing rights to NAPRELAN in late 2006 was the opportunity to offer a differentiated pain therapy in light of the market withdrawal of certain COX-2 inhibitor drugs,” Mr. Heck further stated. “We believe NAPRELAN is an attractive option for pain management. Its active ingredient, naproxen sodium, has a well established efficacy and safety profile, and its patented, controlled release technology provides patients with the convenience of once-daily dosing.”

About NAPRELAN

NAPRELAN (naproxen sodium) Controlled-Release Tablets are commercially available in 375 milligram, 500 milligram and 750 milligram dosage strengths. NAPRELAN 750 milligram is the only 750 milligram strength naproxen / naproxen sodium available in the US market. NAPRELAN Tablets use Elan’s proprietary Intestinal Protective Drug Absorption System (IPDAS®) Technology. This delivery system combines an immediate release component with a sustained release component of microparticles that are widely dispersed, allowing absorption of the active ingredient throughout the gastrointestinal tract and providing convenient once-daily administration. NAPRELAN Tablets are indicated for the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, tendinitis, bursitis and acute gout. It is also indicated for the relief of mild to moderate pain and the tre atment of primary dysmenorrhea.


Important Safety Information

NAPRELAN Tablets are contraindicated in patients with known hypersensitivity to naproxen or naproxen sodium. NAPRELAN Tablets should not be given to patients who have experienced asthma, urticaria, or allergictype reactions after taking aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs). Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported in such patients. Please see full prescribing information including BOXED warning regarding cardiovascular and gastrointestinal risks. Full prescribing information for NAPRELAN Tablets may be obtained in the U.S. from Victory Pharma Professional Services by calling toll free 866-427-6819 or on Victory Pharma's Web site at www.victorypharma.com .


About Victory Pharma

Founded in 2003, Victory Pharma, Inc. is a privately held specialty pharmaceutical company headquartered in San Diego, CA that is focused on acquiring, developing and marketing products to treat pain and related conditions. Victory markets NAPRELAN and other pain products to pain management specialists, rheumatologists, orthopedic surgeons and selected primary care physicians through its physician office-based field sales force. Victory is also developing proprietary products for the treatment of chronic pain and common, opiate-induced side effects. Further information regarding Victory Pharma is available at www.victorypharma.com .

NAPRELAN® is a trademark of Elan Corporation, plc. IPDAS® is a trademark of Elan Pharma Int. Ltd.